Evidence map›Paper›PMID 36778762›Full record

ArticleBiologics : targets & therapy2023

The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment.

Maher Kurdi, Nasser Mulla, Yousef Katib, Taghreed Alsinani, Sahar Hakamy, Bassam Mj Addas, Husam Malibary, Taher F Halawa, Marwa S Farhan, Eyad Faizo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biologics : targets & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maher KurdiDepartment of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.ORCID 0000-0002-8979-3849
Nasser MullaDepartment of Internal Medicine, Faculty of Medicine, Taibah University, Medina, Saudi Arabia.
Yousef KatibDepartment of Radiology, Faculty of Medicine, Taibah University, Madinah, Saudi Arabia.
Taghreed AlsinaniDepartment of Surgery, King Fahad General Hospital, Jeddah, Saudi Arabia.
Sahar HakamyBrain Tumour Unit, KFMRC, King Abdulaziz University, Jeddah, Saudi Arabia.
Bassam Mj AddasDepartment of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Husam MalibaryDepartment of Internal Medicine, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia.ORCID 0000-0003-1314-8031
Taher F HalawaPediatric Hematology and Oncology Consultant, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Marwa S FarhanClinical Pathology Department, Cairo University, Cairo, Egypt.
Eyad FaizoDivision of Neurosurgery, Department of Surgery, Faculty of Medicine, Tabuk University, Tabuk, Saudi Arabia.
Saleh BaeesaDepartment of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-3053-7912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: IDH1 and IDH2 are hotspot mutations commonly identified in WHO-grade 4 astrocytomas. Their association with TAMs has never been investigated. We aim to explore the crosstalk between the IDH1/2 mutation metabolic effect and TAMs in tumour microenvironment and how this relationship affects the tumour recurrence. Patients and Methods: The study included 20 samples of patients with WHO-grade 4 astrocytoma. The alteration hotspot in codon IDH1 Results: IDH1 Conclusion: IDH1

Indexed as

CD204IDH1/2 mutationrecurrenceTAMWHO-grade 4 astrocytoma

Identifiers

PMID36778762
PMCPMC9912343

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.